Company: CMND
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112329
Chunk: 40

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 40
---
. Our insurance policies do not
cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers
the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government
coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have
a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business
conditions and could harm our results of operations.

Several countries, principally
in the Middle East, still restrict doing business with Israel and Israeli companies, and additional countries may impose restrictions
on doing business with Israel and Israeli companies, whether as a result of hostilities in the region or otherwise. In addition, there
have been increased efforts by activists to cause companies, research institutions and consumers to boycott Israeli goods and cooperation
with Israeli-related entities based on Israeli government policies. Such actions, particularly if they become more widespread, may adversely
impact our ability to cooperate with research institutions and collaborate with other third parties. Any hostilities involving Israel,
any interruption or curtailment of trade or scientific cooperation between Israel and its present partners, or a significant downturn
in the economic or financial condition of Israel could adversely affect our business, financial condition and results of operations. We
may also be targeted by cyber terrorists specifically because we may be perceived as an Israeli-related company.

<div align='center'>6

OFFER STATISTICS AND EXPECTED TIMETABLE</div>

We may sell from time to time
pursuant to this prospectus (as may be detailed in prospectus supplements) an indeterminate number of securities as shall have a maximum
aggregate offering price of $50,000,000. The actual per share price of the securities that we will offer pursuant hereto will depend
on a number of factors that may be relevant as of the time of offer (see “Plan of Distribution” below).

<div align='center'>FORWARD-LOOKING STATEMENTS</div>

This prospectus and elsewhere,
including in our most recent annual report on Form 20-F incorporated by reference herein, and other information included or incorporated
by reference in this prospectus and any accompanying prospectus supplement, contains forward-looking statements concerning our business,
operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and
financial performance and condition. Any statements contained herein that are not statements of historical facts may be